Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 180Gastrointestinal 6Thoracic 4Head & Neck 4Genitourinary 3Classical hematology 2Breast 2Sarcoma 1Other solid neoplasm 1

Conditions

Breast Neoplasms 92Triple Negative Breast Neoplasms 38Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Stomach Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Colorectal Neoplasms 6Melanoma 5Cholangiocarcinoma 5Sarcoma 4Prostatic Neoplasms 4Lung Neoplasms 4Inflammatory Breast Neoplasms 4Breast Neoplasms, Male 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Cisplatin × Breast × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡